8-K: PacBio Announces Preliminary Q1 2025 Revenue, Reaffirms 2025 Guidance, and Implements Cost Reduction Plan

PacBio reports preliminary Q1 2025 revenue, reiterates its 2025 revenue guidance of $155 million to $170 million, and initiates a plan to reduce annualized operating expenses by $45 million to $50 million.

Summary

• PacBio announced preliminary unaudited revenue for Q1 2025, reporting $36.9 million compared to $38.8 million in Q1 2024.
• Instrument revenue was $10.8 million, down from $19.0 million in the same quarter last year, while consumable revenue reached a record $20.1 million, up from $16.0 million.
• Service and other revenue increased to $6.0 million from $3.8 million.
• The company is implementing a plan to reduce its annualized non-GAAP operating expense run rate by $45 million to $50 million by year-end.
• PacBio reaffirms its full-year 2025 revenue guidance of $155 million to $170 million and expects non-GAAP gross margin to be between 35% and 40%.
• The company anticipates its 2025 non-GAAP operating expenses to be lower than the previous guidance of $270 million to $280 million and expects a higher ending cash and investments balance than the previous guidance of approximately $260 million.
• PacBio plans to focus on accelerating HiFi sequencing adoption, improving gross margin, and advancing innovation in its long-read sequencing portfolio.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is facing headwinds and implementing cost reductions, it is also reiterating its revenue guidance and focusing on key growth areas. The record consumable revenue is a positive sign.

Positives

• Consumable revenue reached a company record of $20.1 million.
• Vega system orders accelerated in Q1 2025 compared to Q4 2024.
• Annualized Revio pull-through per system was approximately $236,000, in line with expectations.
• The company is taking strategic steps to reduce spending and reinforce its plan to reach positive cash flow by the end of 2027.
• PacBio is focusing on key priorities such as accelerating HiFi sequencing adoption, improving gross margin, and advancing innovation in its long-read sequencing portfolio.

Negatives

• Q1 2025 revenue decreased to $36.9 million from $38.8 million in Q1 2024.
• Instrument revenue decreased to $10.8 million from $19.0 million in Q1 2024.
• The company is implementing workforce reductions to lower operating expenses.
• Ongoing uncertainty in NIH funding and broader economic headwinds are affecting the industry.

Risks

• The company's final financial results for Q1 2025 may differ materially from the preliminary unaudited information.
• The operating expense reductions may have an adverse impact on the company's business and results of operations.
• Charges associated with the operating expense reductions may be greater than anticipated.
• Uncertainty surrounding academic and NIH funding, along with the introduction of new tariffs, could impact the company's ability to place more instruments.

Future Outlook

PacBio reiterates its full-year 2025 revenue guidance of $155 million to $170 million and expects its ending cash and investments balance to be higher than previous guidance of approximately $260 million. The company aims to reach positive cash flow by the end of 2027.

Management Comments

• Christian Henry, President and CEO of PacBio, stated that the company is pleased with its start to the year as revenue met expectations and record levels of consumable revenue were achieved.
• He noted that the Vega launch is progressing well and attracting more customers to HiFi sequencing.
• He also mentioned that the company is taking strategic steps to reduce spending and reinforce its plan to reach positive cash flow by the end of 2027.

Industry Context

The announcement reflects the challenges faced by genomics companies due to macroeconomic headwinds and funding uncertainties, prompting PacBio to streamline operations and focus on core technologies. This is a common strategy in the industry to navigate market volatility and ensure long-term sustainability.

Comparison to Industry Standards

• Illumina, a major competitor in the sequencing market, has also faced similar challenges related to economic conditions and funding, leading to cost-cutting measures and strategic realignments.
• Companies like Oxford Nanopore Technologies, another player in the long-read sequencing space, are also focusing on improving cost-effectiveness and expanding applications to compete effectively.
• The annualized Revio pull-through of $236,000 is a key metric, and its performance relative to other high-throughput sequencing platforms will be closely watched by investors.

Stakeholder Impact

• Shareholders may be concerned about the workforce reductions and decreased revenue, but reassured by the reiterated guidance and cost-saving measures.
• Employees will be affected by the workforce reductions.
• Customers may experience changes in service as the company restructures its commercial organization.

Next Steps

• PacBio will hold its quarterly conference call on May 8, 2025, to discuss its first quarter 2025 financial results.
• The company will finalize its financial results for Q1 2025 in May 2025.

Key Dates

Keywords

PacBio, revenue, sequencing, financial results, guidance, operating expenses, HiFi sequencing, Vega, Revio, cost reduction, workforce reduction